Efficacy and safety of SHEN26, a novel oral small molecular RdRp inhibitor for COVID-19 treatment: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial

Efficacy and safety of SHEN26, a novel oral small molecular RdRp inhibitor for COVID-19 treatment: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial

Abstract Background SHEN26 (ATV014) is an oral RNA-dependent RNA polymerase (RdRp) inhibitor with potential anti-SARS-CoV-2 activity. Safety, tolerability, and pharmacokinetic characteristics were verified in a Phase I study. This phase II study aimed to verify the efficacy and safety of SHEN26 in C...

Full description

Saved in:
Bibliographic Details
Main Authors: Jiangtao Bai, Tetsuya Asakawa, Wenfang Yuan, Yuanlong Lin, Hao Ju, Dandan Xu, Mingming Yang, Shuo Li, Guanguan Li, Deyin Guo, Hongzhou Lu, Xumu Zhang
Format: Article
Language:English
Published: BMC 2025-01-01
Series:Virology Journal
Subjects:
COVID-19
Efficacy and safety
Oral small molecular antiviral drug
RdRp inhibitor
Viral load
Online Access:https://doi.org/10.1186/s12985-025-02631-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12985-025-02631-y

Similar Items